Innodem Neurosciences, a leading digital biomarker & AI company

Artificial Intelligence

Innodem, a company led by a team of neurologists, neuroscientists, AI experts, data scientists, and software engineers, has patented its newly developed technology in North America, Europe, and Asia. The company’s ongoing pipeline of clinical trials in various neurodegenerative disorders provides well-phenotyped patient data that is ingested by various machine learning algorithms to train them to improve predictability models.

Read more
Gaze Mapping Biomarkers (GMBs)

A gaze mapping biomarker, or GMB, is a quantitative measure of human cognition that analyzes the gaze patterns produced while performing short visual tasks. GMBs can help assess cognitive function such as attention, processing speed, working memory, and response inhibition.  GMBs have shown that they can aid in disease tracking.

Read more
Eye Movement Biomarkers (EMBs)

An eye movement biomarker, or EMB, is a quantitative measure of eye movements that can assist to diagnose or monitor various neurological disorders. Some examples of EMBs are saccades, anti-saccades, pursuit, velocity, latency and amplitude.

Read more

Novartis Pharmaceuticals Canada signs a partnership to reimagine medicine and improve access to innovation.

Innodem Explainer Video (1’22” min.)


A Leading Neurologist Joins Innodem Neurosciences

Innodem Neurosciences, a leader in digital health and the convergence of neuroscience, pharmaceuticals and AI, is proud to announce the appointment of a leading authority on neurodegenerative and mental diseases, Dr. Paul Giacomini, M.D., FRCPC, as the company’s Chief Medical Officer.

Read more
Innodem Neurosciences signs a strategic commercial framework agreement with Novartis Pharmaceuticals Canada Inc.

Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Read more
Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software

A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of cortical and subcortical structures and circuits that are susceptible to a variety of degenerative processes. 

Read more
A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease

The idea that eye movements can reflect certain aspects of brain function and inform on the presence of neurodegeneration is not a new one. Indeed, a growing body of research has shown that several neurodegenerative disorders, such as Alzheimer’s and Parkinson’s Disease, present characteristic eye movement anomalies and that specific gaze and eye movement parameters correlate with disease severity.

Read more
ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis

Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye tracking technology for people living with multiple sclerosis has been granted “Breakthrough Device” designation by the U.S. Food & Drug Administration.

Read more
Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Read more

Our Partners